Page 132 - 2021_10-Haematologica-web

L. Paschold et al.
Table 1. Characteristics of malignant B-cell clones in paired samples of nodular lymphocyte-predominant Hodgkin lymphoma cohorts 2 and 3.
Sample Disease status at
sampling
NLPHL01
ID NLPHL
Rel1 NLPHL
Rel2 NLPHL
NLPHL02
ID NLPHL Rel NLPHL
NLPHL03
ID NLPHL Rel NLPHL
NLPHL04
ID NLPHL Rel NLPHL
NLPHL09
ID NLPHL Rel NLPHL
NLPHL14
ID NLPHL Rel NLPHL
NLPHL28
ID NLPHL Rel NLPHL
NLPHL13
ID NLPHL Rel NLPHL
NLPHL15
ID NLPHL Rel NLPHL
NLPHL16
ID NLPHL Rel NLPHL
NLPHL20
ID NLPHL Rel NLPHL
NLPHL10
ID NLPHL Trafo DLBCL
NLPHL11
ID NLPHL Trafo DLBCL
NLPHL32
ID NLPHL Trafo DLBCL
NLPHL35
ID NLPHL Trafo DLBCL
NLPHL33
ID NLPHL Trafo DLBCL
NLPHL34
ID NLPHL Trafo DLBCL
NLPHL41
ID NLPHL Trafo DLBCL
IgD status
positive positive positive
positive positive
negative negative
positive positive
negative negative
positive positive
positive positive
negative negative
negative negative
negative negative
negative negative
negative negative
negative negative
negative negative
negative negative
negative negative
negative negative
negative
negative
Tissue N. of unique IGH
clonotypes
LN 4591 LN 7717 LN 3905
LN 3899 LN 3196
LN 7690 LN 6388
LN 4622 LN 4202
LN 4630 LN 6014
LN 4916 LN 2166
LN 8347 LN 5438
LN 1628 LN 496
LN 7395 LN 5983
LN 1740 LN 731
LN 144 LN 420
LN 396 liver 30
LN 675 spleen 1964
LN 1091 LN 178
LN 3577 LN 16
LN 301 LN 59
LN 444 LN 105
LN 113
LN 39
Characteristics of the malignant clone
Clone fraction (%)
0.65 0.67 0.18
0.07 0.72
0.02 0.32
0.27 0.57
2.82 3.05
0.09 0.17
0.16 5.38
0.14 0.12
0.07 0.07
0.55 2.64
0.02 1.16
6.,4 91.1
26.3 33.2*
19.4 94.3
1.34 80.2*
68.3* 92.6
CDR3 length (nt)
84 84 84
84 84
105 105
96 96
78 78
81 81
96 96
54 54
45 45
69 69
42 42
66 66
63 63
39 39
63 63
45 54
IGHV/D/J rearrangement
IGHV3 IGHD3-3 IGHJ6 IGHV3 IGHD3-3 IGHJ6 IGHV3 IGHD3-3 IGHJ6
IGHV3 IGHD3-3 IGHJ6 IGHV3 IGHD3-3 IGHJ6
IGHV4 IGHD3-3 IGHJ6 IGHV4 IGHD3-3 IGHJ6
IGHV3 IGHD3-3 IGHJ6 IGHV3 IGHD3-3 IGHJ6
IGHV3 IGHD2-2 IGHJ6 IGHV3 IGHD2-2 IGHJ6
IGHV3 IGHD3-3 IGHJ6 IGHV3 IGHD3-3 IGHJ6
IGHV3 IGHD3-3 IGHJ6 IGHV3 IGHD3-3 IGHJ6
IGHV4 IGHD1-26 IGHJ3 IGHV4 IGHD1-26 IGHJ3
IGHV3 IGHD2-2 IGHJ5 IGHV3 IGHD2-2 IGHJ5
IGHV3 IGHD-3-16 IGHJ6 IGHV3 IGHD-3-16 IGHJ6
IGHV3 IGHD-6-19 IGHJ4 IGHV3 IGHD-6-19 IGHJ4
IGHV3 IGHD7-27 IGHJ6 IGHV3 IGHD7-27 IGHJ6
IGHV2 IGHD2-2 IGHJ4 IGHV2 IGHD2-2 IGHJ4
IGHV4 IGHD6-6 IGHJ4 IGHV4 IGHD6-6 IGHJ4
IGHV2-70 IGHD2-8 IGHJ6 IGHV2-70 IGHD2-8 IGHJ6
IGHV4 IGHD1-1 IGHJ3 IGHV3 IGHD6-19 IGHJ4
CDR3 amino acid sequence
CARVAGAAGRNYNYWSGYWEDYYFMDVW CARVAGAAGRNYNYWSGYWEDYYFMDVW CARVAGAAGRNYNYWSGYWEDYYFMDVW
CAREVLRWGGSYDFWSNYYEDYFALDVW CAREVLRWGGSYDFWSSYYEDYFALDVW
CTKGSIVSVRGSSKYYGFWNGYYGQDYVYYFMDVW CTKGSIVSVRGSSKYYGFWNGYYGQDYVYYFMDVW
CAKCHLYAIRGKTYSFWSRYWEAYHYYDMDVW CAKCHLYAIRGKTYSFWSRYWEAYHYYDMDVW
CARGRRGYCSSTRCYNGYYYYGMDVW CARGRRGYCSSTRCYNGYYYYGMDVW
CARIGAARGLYFDFWSFYEDYYYMDVW CARIGAARGLYFDFWSFYEDYYYMDVW
CARDIYRRGWGKYYDFWSGYSEGAEEYGMDVW CARDIYRRGWGKYYDFWSGYSEGAEEYGMDVW
CARPRAVGATRGDAYYIW CARPRAVGATRGDAYYIW
CAMGGTALRLGLFAW CAMGGTALRLGLFAW
CAKDREPSLIRRLHQLYYGLDVW CAKDREPSLIRRLHQLYYGLDVW
CARWIAVAGVFDYW CARWIAVAGVFDYW
CARKGGDPVLAVFVPNFALNVW CARKGGDPVLAVFVPNFALNVW
CGHNADSRPAFIDLHKPIDSW CRYIVDSRPAFSHLHKAIDSW
CAGGLSGHYCHYW CAGGLSGHYCHYW
CARIVRFRNFLSVDYHGMDVW CARIEIFRNFLLFNYNGMDVW
CAKTSRSVRHAYDVW CAKDIRNVGSSGWYFDYW
- CTRSAGNRWKIVQYHAMDVW
-
CARVGSWREDYW
- - -
17.5 60 IGHV3 IGHJ6
- - -
16.8 36 IGHV4 IGHD1-1 IGHJ4
Only cases with identified malignant rearrangements are shown. ID: initial diagnosis; Rel: relapse; Trafo: transformation; LN: lymph node. *Sum of fraction of homologous clones (see also Figures 6 and 7).
2660
haematologica | 2021; 106(10)